Insider Transactions in Q2 2024 at Revolution Medicines, Inc. (RVMD)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 26
2024
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-3.88%
|
$76,000
$38.47 P/Share
|
|
Jun 25
2024
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
16,467
-5.77%
|
$642,213
$39.06 P/Share
|
|
Jun 25
2024
|
Stephen Michael Kelsey |
BUY
Exercise of conversion of derivative security
|
Direct |
16,467
+5.45%
|
$65,868
$4.09 P/Share
|
|
Jun 24
2024
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
200
-0.07%
|
$7,800
$39.0 P/Share
|
|
Jun 24
2024
|
Stephen Michael Kelsey |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.07%
|
$800
$4.09 P/Share
|
|
Jun 20
2024
|
Elizabeth M Anderson |
BUY
Grant, award, or other acquisition
|
Direct |
4,800
+18.88%
|
-
|
|
Jun 20
2024
|
Flavia Borellini |
BUY
Grant, award, or other acquisition
|
Direct |
4,800
+17.63%
|
-
|
|
Jun 20
2024
|
Barbara Weber |
BUY
Grant, award, or other acquisition
|
Direct |
4,800
+18.88%
|
-
|
|
Jun 20
2024
|
Lorence H. Kim |
BUY
Grant, award, or other acquisition
|
Direct |
4,800
+6.37%
|
-
|
|
Jun 20
2024
|
Alexis Borisy |
BUY
Grant, award, or other acquisition
|
Direct |
4,800
+0.21%
|
-
|
|
Jun 20
2024
|
Sushil Patel |
BUY
Grant, award, or other acquisition
|
Direct |
4,800
+18.97%
|
-
|
|
Jun 20
2024
|
Sandra Horning |
BUY
Grant, award, or other acquisition
|
Direct |
4,800
+4.8%
|
-
|
|
Jun 17
2024
|
Lin Wei Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,589
-7.31%
|
$206,793
$37.39 P/Share
|
|
Jun 17
2024
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,757
-3.3%
|
$65,009
$37.39 P/Share
|
|
Jun 17
2024
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
3,349
-1.23%
|
$123,913
$37.39 P/Share
|
|
Jun 17
2024
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,415
-3.13%
|
$163,355
$37.39 P/Share
|
|
Jun 17
2024
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,893
-1.84%
|
$70,041
$37.39 P/Share
|
|
Jun 17
2024
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
11,950
-3.69%
|
$442,150
$37.39 P/Share
|
|
Jun 03
2024
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
7,500
-0.76%
|
$300,000
$40.0 P/Share
|
|
Jun 03
2024
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+2.22%
|
$30,000
$4.09 P/Share
|
|
May 21
2024
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,500
-1.39%
|
$58,500
$39.09 P/Share
|
|
May 03
2024
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.93%
|
$400,000
$40.03 P/Share
|
|
May 03
2024
|
Jack Anders Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.2%
|
$20,000
$2.68 P/Share
|
|
Apr 10
2024
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Indirect |
10,000
-14.11%
|
$350,000
$35.34 P/Share
|
|
Apr 10
2024
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
7,500
-1.63%
|
$262,500
$35.48 P/Share
|
|
Apr 10
2024
|
Sushil Patel |
SELL
Open market or private sale
|
Direct |
2,155
-12.07%
|
$79,735
$37.0 P/Share
|
|
Apr 10
2024
|
Sushil Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,155
+10.77%
|
$34,480
$16.8 P/Share
|